Nitish R Mahapatra

List of Publications by Year
in descending order

68	1,968	236612 25	264894 42
papers	citations	h-index	g-index

74	74	74	1898
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. Journal of Clinical Investigation, 2005, 115, 1942-1952.	3.9	277
2	Both Rare and Common Polymorphisms Contribute Functional Variation at CHGA, a Regulator of Catecholamine Physiology. American Journal of Human Genetics, 2004, 74, 197-207.	2.6	104
3	The Catecholamine Release-Inhibitory â€œCatestatinâ€•Fragment of Chromogranin A: Naturally Occurring Human Variants with Different Potencies for Multiple Chromaffin Cell Nicotinic Cholinergic Responses. Molecular Pharmacology, 2004, 66, 1180-1191.	1.0	86
4	Catecholamine Secretory Vesicle Stimulus-Transcription Coupling in Vivo. Journal of Biological Chemistry, 2003, 278, 32058-32067.	1.6	73
5	Identification of a novel sorting determinant for the regulated pathway in the secretory protein chromogranin A. Journal of Cell Science, 2002, 115, 4827-4841.	1.2	72
6	Organic Anion Transporter 3 Contributes to the Regulation of Blood Pressure. Journal of the American Society of Nephrology: JASN, 2008, 19, 1732-1740.	3.0	72
7	Catestatin is a novel endogenous peptide that regulates cardiac function and blood pressure. Cardiovascular Research, 2008, 80, 330-338.	1.8	66
8	Common Genetic Mechanisms of Blood Pressure Elevation in Two Independent Rodent Models of Human Essential Hypertension. American Journal of Hypertension, 2005, 18, 633-652.	1.0	65
9	Enhancement in the efficiency of polymerase chain reaction by TiO₂nanoparticles: crucial role of enhanced thermal conductivity. Nanotechnology, 2010, 21, 255704.	1.3	59
10	Catestatin: A Master Regulator of Cardiovascular Functions. Current Medicinal Chemistry, 2018, 25, 1352-1374.	1.2	52
11	A Dynamic Pool of Calcium in Catecholamine Storage Vesicles. Journal of Biological Chemistry, 2004, 279, 51107-51121.	1.6	51
12	MicroRNA-22 and promoter motif polymorphisms at the Chga locus in genetic hypertension: functional and therapeutic implications for gene expression and the pathogenesis of hypertension. Human Molecular Genetics, 2013, 22, 3624-3640.	1.4	46
13	Coordinated Transcriptional Regulation of Hspa1a Gene by Multiple Transcription Factors: Crucial Roles for HSF-1, NF-Y, NF-Î°B, and CREB. Journal of Molecular Biology, 2014, 426, 116-135.	2.0	45
14	Extreme tolerance to cadmium and high resistance to copper, nickel and zinc in different Acidiphilium strains. Letters in Applied Microbiology, 1996, 23, 393-397.	1.0	43
15	Molecular mechanism of monoamine oxidase A gene regulation under inflammation and ischemiaâ€like conditions: key roles of the transcription factors <scp>GATA</scp>2, Sp1 and <scp>TBP</scp>. Journal of Neurochemistry, 2015, 134, 21-38.	2.1	39
16	Neuroendocrine Transcriptome in Genetic Hypertension. Hypertension, 2004, 43, 1301-1311.	1.3	37
17	The chromogranin A fragment catestatin: specificity, potency and mechanism to inhibit exocytotic secretion of multiple catecholamine storage vesicle co-transmitters. Journal of Hypertension, 2006, 24, 895-904.	0.3	35
18	Association of MMP7 â^'181Aâ†'G Promoter Polymorphism with Gastric Cancer Risk. Journal of Biological Chemistry, 2015, 290, 14391-14406.	1.6	34

#	Article	IF	Citations
19	Bio-effective disease control and plant growth promotion in lentil by two pesticide degrading strains of Bacillus sp.. Biological Control, 2018, 127, 55-63.	1.4	32
20	Catecholamine storage vesicles and the metabolic syndrome: the role of the chromogranin A fragment pancreastatin. Diabetes, Obesity and Metabolism, 2006, 8, 621-633.	2.2	31
21	Chromogranin A: a novel susceptibility gene for essential hypertension. Cellular and Molecular Life Sciences, 2010, 67, 861-874.	2.4	31
22	Transcriptional Regulation of the Novel Monoamine Oxidase Renalase: Crucial Roles of Transcription Factors Sp1, STAT3, and ZBP89. Biochemistry, 2014, 53, 6878-6892.	1.2	30
23	Molecular mechanism of interactions of the physiological anti-hypertensive peptide catestatin with the neuronal nicotinic acetylcholine receptor. Journal of Cell Science, 2012, 125, 2323-37.	1.2	29
24	Conformational preferences and activities of peptides from the catecholamine release-inhibitory (catestatin) region of chromogranin A. Regulatory Peptides, 2004, 118, 75-87.	1.9	27
25	Molecular basis of neuroendocrine cell type-specific expression of the chromograninâ€ƒB gene: crucial role of the transcription factors CREB, AP-2, Egr-1 and Sp1. Journal of Neurochemistry, 2006, 99, 119-133.	2.1	27
26	Common genetic variants in the chromogranin A promoter alter autonomic activity and blood pressure. Kidney International, 2008, 74, 115-125.	2.6	27
27	Secretin Activation of Chromogranin A Gene Transcription. Journal of Biological Chemistry, 2003, 278, 19986-19994.	1.6	26
28	Genetic regulation of catecholamine synthesis, storage and secretion in the spontaneously hypertensive rat. Human Molecular Genetics, 2010, 19, 2567-2580.	1.4	25
29	MicroRNA 27a Is a Key Modulator of Cholesterol Biosynthesis. Molecular and Cellular Biology, 2020, 40, .	1.1	25
30	Chromogranin A regulates vesicle storage and mitochondrial dynamics to influence insulin secretion. Cell and Tissue Research, 2017, 368, 487-501.	1.5	24
31	Functional Genetic Variants of the Catecholamine-Release-Inhibitory Peptide Catestatin in an Indian Population. Journal of Biological Chemistry, 2012, 287, 43840-43852.	1.6	23
32	Neuroendocrine Cell Type-Specific and Inducible Expression of the Chromogranin B Gene: Crucial Role of the Proximal Promoter*. Endocrinology, 2000, 141, 3668-3678.	1.4	22
33	The trans-Golgi Proteins SCLIP and SCG10 Interact with Chromogranin A To Regulate Neuroendocrine Secretion. Biochemistry, 2008, 47, 7167-7178.	1.2	21
34	Catestatin Gly364Ser Variant Alters Systemic Blood Pressure and the Risk for Hypertension in Human Populations via Endothelial Nitric Oxide Pathway. Hypertension, 2016, 68, 334-347.	1.3	21
35	Plasmid curing from an acidophilic bacterium of the genusAcidocella. FEMS Microbiology Letters, 2000, 183, 271-274.	0.7	19
36	Naturally Occurring Variants of the Dysglycemic Peptide Pancreastatin. Journal of Biological Chemistry, 2014, 289, 4455-4469.	1.6	19

#	Article	IF	Citations
37	Pleiotropic effects of novel trans-acting loci influencing human sympathochromaffin secretion. Physiological Genomics, 2006, 25, 470-479.	1.0	18
38	Post-Transcriptional Regulation of Renalase Gene by miR-29 and miR-146 MicroRNAs: Implications for Cardiometabolic Disorders. Journal of Molecular Biology, 2015, 427, 2629-2646.	2.0	17
39	Resistance to Cadmium and Zinc in Acidiphilium symbioticum KM2 Is Plasmid Mediated. Current Microbiology, 2002, 45, 180-186.	1.0	16
40	The angiotensin II receptor (Agtr1a): functional regulatory polymorphisms in a locus genetically linked to blood pressure variation in the mouse. Physiological Genomics, 2003, 14, 83-93.	1.0	16
41	Global metabolic consequences of the chromogranin A-null model of hypertension: transcriptomic detection, pathway identification, and experimental verification. Physiological Genomics, 2010, 40, 195-207.	1.0	16
42	Functional Promoter Polymorphisms Govern Differential Expression of HMG-CoA Reductase Gene in Mouse Models of Essential Hypertension. PLoS ONE, 2011, 6, e16661.	1.1	16
43	A common genetic variant of the chromogranin A-derived peptide catestatin is associated with atherogenesis and hypertension in a Japanese population. Endocrine Journal, 2015, 62, 797-804.	0.7	15
44	Catestatin reverses the hypertrophic effects of norepinephrine in H9c2 cardiac myoblasts by modulating the adrenergic signaling. Molecular and Cellular Biochemistry, 2020, 464, 205-219.	1.4	14
45	Neuroendocrine Cell Typeâ€Specific and Inducible Expression of Chromogranin/Secretogranin Genes. Annals of the New York Academy of Sciences, 2002, 971, 27-38.	1.8	12
46	Molecular interactions of the physiological anti-hypertensive peptide catestatin with the neuronal nicotinic acetylcholine receptor. Journal of Cell Science, 2012, 125, 2787-2787.	1.2	11
47	Regulation of Monoamine Oxidase B Gene Expression: Key Roles for Transcription Factors Sp1, Egr1 and CREB, and microRNAs miR-300 and miR-1224. Journal of Molecular Biology, 2019, 431, 1127-1147.	2.0	10
48	Key regulatory miRNAs in lipid homeostasis: Implications for cardiometabolic diseases and development of novel therapeutics. Drug Discovery Today, 2022, 27, 2170-2180.	3.2	9
49	Integration of Metal-Resistant Determinants from the Plasmid of an Acidocella Strain into the Chromosome of Escherichia coli DH5?*. Current Microbiology, 2005, 50, 28-32.	1.0	8
50	Genotyping and meta-analysis of KIF6 Trp719Arg polymorphism in South Indian Coronary Artery Disease patients: A caseâ€“control study. Meta Gene, 2015, 5, 129-134.	0.3	8
51	Neuroendocrine Cell Type-Specific and Inducible Expression of the Chromogranin B Gene: Crucial Role of the Proximal Promoter. , 0, .		8
52	Chromaffin Cell Catecholamine Secretion: Bisindolylmaleimide Compounds Exhibit Novel and Potent Antagonist Effects at the Nicotinic Cholinergic Receptor in Pheochromocytoma Cells. Molecular Pharmacology, 2002, 61, 1340-1347.	1.0	7
53	Intracellular Protein Trafficking into Catecholamine Storage Vesicles. Annals of the New York Academy of Sciences, 2002, 971, 262-265.	1.8	7
54	Integrated Computational and Experimental Analysis of the Neuroendocrine Transcriptome in Genetic Hypertension Identifies Novel Control Points for the Cardiometabolic Syndrome. Circulation: Cardiovascular Genetics, 2012, 5, 430-440.	5.1	6

#	Article	IF	Citations
55	A haplotype variant of the human chromogranin A gene (CHGA) promoter increases CHGA expression and the risk for cardiometabolic disorders. Journal of Biological Chemistry, 2017, 292, 13970-13985.	1.6	5
56	Functional promoter polymorphisms direct the expression of cystathionine gamma-lyase gene in mouse models of essential hypertension. Journal of Molecular and Cellular Cardiology, 2017, 102, 61-73.	0.9	5
57	Generation of Novel Plasmids in Escherichia coli S17-1(pSUP106). Current Microbiology, 2003, 46, 318-323.	1.0	4
58	Catecholamine biosynthesis and secretion: physiological and pharmacological effects of secretin. Cell and Tissue Research, 2011, 345, 87-102.	1.5	4
59	PCR-based segregation of one hybrid variety of Labeo rohita and Catla catla from their wild-types. Aquaculture International, 2014, 22, 775-782.	1.1	4
60	A Common Tag Nucleotide Variant in MMP7 Promoter Increases Risk for Hypertension via Enhanced Interactions With CREB (Cyclic AMP Response Element-Binding Protein) Transcription Factor. Hypertension, 2019, 74, 1448-1459.	1.3	4
61	Functional Gly297Ser Variant of the Physiological Dysglycemic Peptide Pancreastatin Is a Novel Risk Factor for Cardiometabolic Disorders. Diabetes, 2022, 71, 538-553.	0.3	4
62	Hypoxia-mediated regulation of mitochondrial transcription factors in renal epithelial cells: implications for hypertensive renal physiology. Hypertension Research, 2021, 44, 154-167.	1.5	3
63	Cloning of metal-resistance conferring genes from an Acidocella strain. Process Metallurgy, 1999, , 21-28.	0.1	2
64	An evolutionarily-conserved promoter allele governs HMG-CoA reductase expression in spontaneously hypertensive rat. Journal of Molecular and Cellular Cardiology, 2021, 158, 140-152.	0.9	2
65	Role of Monoamine Oxidases in Heart Diseases. , 2019, , 129-150.		1
66	Catestatin, the catecholamine release-inhibitory peptide fragment of chromogranin A: Naturally occurring human variants displaying different potencies for multiple nicotinic cholinergic responses in chromaffin cells. Clinical Pharmacology and Therapeutics, 2005, 77, P6-P6.	2.3	0
67	Molecular basis of altered expression of the HMG-CoA reductase gene in genetically hypertensive mice. International Journal of Cardiology, 2009, 137, S107.	0.8	0
68	Identification and Functional Characterization of Genetic Variants of the Catecholamine Release-Inhibitory Peptide Catestatin in an Indian Population. , 2014, , 198-199.		0